Tags

Type your tag names separated by a space and hit enter

A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
Elife. 2022 08 25; 11E

Abstract

Large-scale populations in the world have been vaccinated with COVID-19 vaccines, however, breakthrough infections of SARS-CoV-2 are still growing rapidly due to the emergence of immune-evasive variants, especially Omicron. It is urgent to develop effective broad-spectrum vaccines to better control the pandemic of these variants. Here, we present a mosaic-type trimeric form of spike receptor-binding domain (mos-tri-RBD) as a broad-spectrum vaccine candidate, which carries the key mutations from Omicron and other circulating variants. Tests in rats showed that the designed mos-tri-RBD, whether used alone or as a booster shot, elicited potent cross-neutralizing antibodies against not only Omicron but also other immune-evasive variants. Neutralizing antibody ID50 titers induced by mos-tri-RBD were substantially higher than those elicited by homo-tri-RBD (containing homologous RBDs from prototype strain) or the BIBP inactivated COVID-19 vaccine (BBIBP-CorV). Our study indicates that mos-tri-RBD is highly immunogenic, which may serve as a broad-spectrum vaccine candidate in combating SARS-CoV-2 variants including Omicron.

Links

PMC Free PDF

Authors+Show Affiliations

Zhang J
The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China. National Engineering Center for New Vaccine Research, Beijing, China.
Han ZB
The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China. National Engineering Center for New Vaccine Research, Beijing, China.
Liang Y
The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China. National Engineering Center for New Vaccine Research, Beijing, China.
Zhang XF
The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China. National Engineering Center for New Vaccine Research, Beijing, China.
Jin YQ
The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China.
Du LF
The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China. National Engineering Center for New Vaccine Research, Beijing, China.
Shao S
The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China. National Engineering Center for New Vaccine Research, Beijing, China.
Wang H
Beijing Institute of Biological Products Company Limited, Beijing, China.
Hou JW
The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China. National Engineering Center for New Vaccine Research, Beijing, China.
Xu K
National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
Lei W
National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
Lei ZH
The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China. National Engineering Center for New Vaccine Research, Beijing, China.
Liu ZM
The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China. National Engineering Center for New Vaccine Research, Beijing, China.
Zhang J
Beijing Institute of Biological Products Company Limited, Beijing, China.
Hou YN
The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China. National Engineering Center for New Vaccine Research, Beijing, China.
Liu N
The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China. National Engineering Center for New Vaccine Research, Beijing, China.
Shen FJ
The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China. National Engineering Center for New Vaccine Research, Beijing, China.
Wu JJ
The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China. National Engineering Center for New Vaccine Research, Beijing, China.
Zheng X
The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China. National Engineering Center for New Vaccine Research, Beijing, China.
Li XY
The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China. National Engineering Center for New Vaccine Research, Beijing, China.
Li X
The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China. National Engineering Center for New Vaccine Research, Beijing, China.
Huang WJ
National Institutes for Food and Drug Control (NIFDC), Beijing, China.
Wu GZ
National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
Su JG
The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China. National Engineering Center for New Vaccine Research, Beijing, China.
Li QM
The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China. National Engineering Center for New Vaccine Research, Beijing, China.

MeSH

AnimalsAntibodies, NeutralizingAntibodies, ViralBroadly Neutralizing AntibodiesCOVID-19COVID-19 VaccinesHumansRatsSARS-CoV-2Spike Glycoprotein, Coronavirus

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

36004719

Citation

Zhang, Jing, et al. "A Mosaic-type Trimeric RBD-based COVID-19 Vaccine Candidate Induces Potent Neutralization Against Omicron and Other SARS-CoV-2 Variants." ELife, vol. 11, 2022.
Zhang J, Han ZB, Liang Y, et al. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants. Elife. 2022;11.
Zhang, J., Han, Z. B., Liang, Y., Zhang, X. F., Jin, Y. Q., Du, L. F., Shao, S., Wang, H., Hou, J. W., Xu, K., Lei, W., Lei, Z. H., Liu, Z. M., Zhang, J., Hou, Y. N., Liu, N., Shen, F. J., Wu, J. J., Zheng, X., ... Li, Q. M. (2022). A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants. ELife, 11. https://doi.org/10.7554/eLife.78633
Zhang J, et al. A Mosaic-type Trimeric RBD-based COVID-19 Vaccine Candidate Induces Potent Neutralization Against Omicron and Other SARS-CoV-2 Variants. Elife. 2022 08 25;11 PubMed PMID: 36004719.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants. AU - Zhang,Jing, AU - Han,Zi Bo, AU - Liang,Yu, AU - Zhang,Xue Feng, AU - Jin,Yu Qin, AU - Du,Li Fang, AU - Shao,Shuai, AU - Wang,Hui, AU - Hou,Jun Wei, AU - Xu,Ke, AU - Lei,Wenwen, AU - Lei,Ze Hua, AU - Liu,Zhao Ming, AU - Zhang,Jin, AU - Hou,Ya Nan, AU - Liu,Ning, AU - Shen,Fu Jie, AU - Wu,Jin Juan, AU - Zheng,Xiang, AU - Li,Xin Yu, AU - Li,Xin, AU - Huang,Wei Jin, AU - Wu,Gui Zhen, AU - Su,Ji Guo, AU - Li,Qi Ming, Y1 - 2022/08/25/ PY - 2022/03/14/received PY - 2022/08/22/accepted PY - 2022/8/26/pubmed PY - 2022/9/21/medline PY - 2022/8/25/entrez KW - COVID-19 KW - SARS-CoV-2 KW - broad-spectrum KW - immunology KW - infectious disease KW - inflammation KW - microbiology KW - omicron variant KW - vaccine KW - viruses JF - eLife JO - Elife VL - 11 N2 - Large-scale populations in the world have been vaccinated with COVID-19 vaccines, however, breakthrough infections of SARS-CoV-2 are still growing rapidly due to the emergence of immune-evasive variants, especially Omicron. It is urgent to develop effective broad-spectrum vaccines to better control the pandemic of these variants. Here, we present a mosaic-type trimeric form of spike receptor-binding domain (mos-tri-RBD) as a broad-spectrum vaccine candidate, which carries the key mutations from Omicron and other circulating variants. Tests in rats showed that the designed mos-tri-RBD, whether used alone or as a booster shot, elicited potent cross-neutralizing antibodies against not only Omicron but also other immune-evasive variants. Neutralizing antibody ID50 titers induced by mos-tri-RBD were substantially higher than those elicited by homo-tri-RBD (containing homologous RBDs from prototype strain) or the BIBP inactivated COVID-19 vaccine (BBIBP-CorV). Our study indicates that mos-tri-RBD is highly immunogenic, which may serve as a broad-spectrum vaccine candidate in combating SARS-CoV-2 variants including Omicron. SN - 2050-084X UR - https://www.unboundmedicine.com/medline/citation/36004719/A_mosaic_type_trimeric_RBD_based_COVID_19_vaccine_candidate_induces_potent_neutralization_against_Omicron_and_other_SARS_CoV_2_variants_ DB - PRIME DP - Unbound Medicine ER -